Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART
Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Paolo Strati(The University of Texas MD Anderson Cancer Center), Jeremy Ramdial(The University of Texas MD Anderson Cancer Center), Jaimole Varghese(The University of Texas MD Anderson Cancer Center), Karla Ow(The University of Texas MD Anderson Cancer Center), Amy Ayers(The University of Texas MD Anderson Cancer Center), Timothy Voorhees(University of North Carolina at Chapel Hill), Youssef Youssef(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Michael D. Jain(Moffitt Cancer Center), Xiaowen Sun(The University of Texas MD Anderson Cancer Center), Frederick L Locke(Moffitt Cancer Center), Sattva S Neelapu(The University of Texas MD Anderson Cancer Center), Narendranath Epperla(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Zachary Hunzeker(The University of Texas MD Anderson Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Julio Chavez(Moffitt Cancer Center), Minifrida Santiago(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(The University of Texas MD Anderson Cancer Center), Ryan Sun(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Outcomes of <i>TP53</i>‐mutant acute myeloid leukemia with decitabine and venetoclax
|Cancer|2021|159
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity
|Blood Advances|2021|146
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
|Clinical Cancer Research|2020|115
Venetoclax resistance: mechanistic insights and future strategies
|Cancer Drug Resistance|2022|103